InnoAul Overview
- Status
-
Private
- Latest Deal Type
-
Seed
- Investors
-
2
InnoAul General Information
Description
Operator of an AI biomedical company intended to deliver precision diagnostics for atopic dermatitis and other chronic skin diseases using RNA transcriptome analysis and minimally invasive technologies. The company offers a diagnostic value chain that combines microneedle-based minimally invasive patches, RNA transcriptome analysis and AI-driven patient classification, enabling customers to achieve accurate, patient-friendly diagnostics, predict treatment responses and develop personalized therapeutic strategies.
Contact Information
Corporate Office
- Seoul
- South Korea
Corporate Office
- Seoul
- South Korea
InnoAul Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 04-Feb-2026 | Completed | Startup |
InnoAul Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CNT Tech | Accelerator/Incubator | Minority | ||
| DB Capital | Corporation | Minority |
InnoAul FAQs
-
Where is InnoAul headquartered?
InnoAul is headquartered in Seoul, South Korea.
-
What industry is InnoAul in?
InnoAul’s primary industry is Biotechnology.
-
Is InnoAul a private or public company?
InnoAul is a Private company.
-
What is InnoAul’s current revenue?
The current revenue for InnoAul is .
-
Who are InnoAul’s investors?
CNT Tech and DB Capital have invested in InnoAul.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process